Mechanism of action
Vortioxetine exhibits a multimodal mechanism of action distinct from traditional selective serotonin reuptake inhibitors. It inhibits the serotonin transporter (SERT), blocking reuptake of serotonin from the synaptic cleft, similar to conventional SSRIs. However, vortioxetine also directly modulates multiple serotonin receptor subtypes.
Receptor activity profile:
- 5-HT3 receptor antagonist – blocks inhibitory effects on acetylcholine and other neurotransmitters
- 5-HT7 receptor antagonist – may enhance glutamatergic activity
- 5-HT1D receptor antagonist – modulates serotonergic neurotransmission
- 5-HT1B receptor partial agonist – modulates serotonin release
- 5-HT1A receptor agonist – reduces anxiety and enhances serotonergic tone
This combination of SERT inhibition and receptor modulation increases serotonin availability while simultaneously fine-tuning receptor-mediated effects. The 5-HT3 antagonism particularly enhances release of dopamine, norepinephrine, acetylcholine, and histamine in cortical and hippocampal regions. This multimodal activity is hypothesized to contribute to improvements in cognitive function (attention, processing speed, executive function) beyond traditional antidepressant effects on mood. The net result is increased monoaminergic neurotransmission in key brain regions involved in mood regulation and cognition.
- Vortioxetine has a multimodal mechanism: SERT inhibition PLUS 5-HT3, 5-HT7 antagonism and 5-HT1A agonism
- Main indication is major depressive disorder in adults; may improve cognitive function in depression
- Metabolized primarily by CYP2D6; dose reduction needed in CYP2D6 poor metabolizers
- Nausea is the most common adverse effect and most frequent reason for discontinuation
- Black box warning for suicidality in patients under age 25, like all antidepressants
- Contraindicated with MAOIs; requires a 14-day washout after stopping an MAOI and a 21-day washout after stopping vortioxetine before starting an MAOI
- Lower rates of sexual dysfunction compared to traditional SSRIs in clinical trials
- Half-life ~66 hours allows once-daily dosing; steady state in 2 weeks
Indications
Major depressive disorder (MDD) is the primary FDA-approved indication for vortioxetine in adults. It is used for acute treatment and maintenance therapy to prevent recurrence of depressive episodes.
Vortioxetine may be particularly considered in patients with MDD who experience cognitive dysfunction as part of their depression, given preclinical and clinical evidence suggesting cognitive benefits. However, it is not specifically approved for cognitive impairment outside the context of depression.
The drug has not been studied extensively in pediatric populations and is not approved for use in children or adolescents with MDD. It is also not indicated for bipolar depression or other psychiatric conditions outside unipolar major depression.
Pharmacokinetics
Absorption: Vortioxetine is well absorbed after oral administration, with absolute bioavailability of approximately 75%. Peak plasma concentrations occur within 7 to 11 hours. Food does not significantly affect absorption.
Distribution: The drug is highly protein-bound (98-99%) and has a large volume of distribution, indicating extensive tissue distribution.
Metabolism: Vortioxetine undergoes extensive hepatic metabolism, primarily via oxidation by CYP2D6 and to a lesser extent by CYP3A4, CYP2C19, CYP2C9, CYP2A6, and CYP2C8. The major metabolite is pharmacologically inactive. CYP2D6 poor metabolizers achieve approximately twice the plasma concentration of extensive metabolizers.
Elimination: The terminal half-life is approximately 66 hours, allowing for once-daily dosing. Steady-state concentrations are reached in about two weeks. Excretion occurs primarily in urine (59%) and feces (26%), mostly as metabolites.
Special populations: Dose adjustment is recommended for known CYP2D6 poor metabolizers. No dose adjustment is needed based on age, renal impairment, or mild-to-moderate hepatic impairment, though vortioxetine has not been studied in severe hepatic impairment.
Adverse effects
Common adverse effects (occurring in ≥5% of patients and at least twice placebo rate):
- Nausea (most common, dose-related, often transient)
- Constipation
- Vomiting
- Sexual dysfunction (less common than traditional SSRIs but still reported)
- Dizziness
- Dry mouth
- Diarrhea
- Flatulence
- Abnormal dreams
Nausea is the most frequent reason for discontinuation during clinical trials. Taking the medication with food may reduce gastrointestinal symptoms.
Serious adverse effects
Serotonin syndrome: Risk increases when combined with other serotonergic agents (SSRIs, SNRIs, triptans, tramadol, MAOIs). Presents with agitation, confusion, tachycardia, hyperthermia, hyperreflexia, and clonus.
Abnormal bleeding: SSRIs and related drugs impair platelet aggregation. Risk is increased with concurrent NSAIDs, aspirin, or anticoagulants.
Activation of mania/hypomania: Can precipitate manic episodes in patients with undiagnosed bipolar disorder.
Angle-closure glaucoma: Pupillary dilation can trigger angle closure in susceptible individuals.
Hyponatremia: SIADH can occur, especially in elderly patients and those on diuretics.
Discontinuation syndrome: Abrupt cessation may cause irritability, agitation, dizziness, sensory disturbances, anxiety, and confusion. Gradual tapering is recommended.
Suicidality: Black box warning for increased risk of suicidal thinking and behavior in children, adolescents, and young adults (up to age 24) during initial treatment. Close monitoring is essential during the first few months of therapy and after dose changes.
Contraindications and warnings
Absolute contraindications:
- Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI
- Use within 21 days of discontinuing vortioxetine before starting an MAOI
- Hypersensitivity to vortioxetine or any formulation component
Black box warning: Antidepressants increase the risk of suicidal thoughts and behaviors in pediatric and young adult patients (ages 24 and younger) with major depressive disorder and other psychiatric disorders. Patients should be monitored closely for clinical worsening, suicidality, or unusual changes in behavior, especially during initial therapy or dose adjustments.
Warnings and precautions:
- Pregnancy: Limited human data. Animal studies show developmental toxicity at higher exposures. Use only if benefit justifies potential fetal risk. Neonates exposed late in pregnancy may experience complications including respiratory distress and feeding difficulty.
- Lactation: Vortioxetine is present in human milk in small amounts. Consider risks and benefits.
- Bipolar disorder: Screen patients for bipolar disorder before initiating treatment, as antidepressants may precipitate mixed/manic episodes.
- Elderly patients: Increased risk of hyponatremia (SIADH).
- Seizure disorder: Use with caution; not systematically evaluated in patients with seizure disorders.
- Hepatic impairment: No adjustment needed for mild-to-moderate impairment; not studied in severe impairment.
Drug interactions
Major interactions:
| Interacting drug | Effect | Management |
|---|---|---|
| MAOIs (phenelzine, tranylcypromine) | Serotonin syndrome, hypertensive crisis | Contraindicated; 14-day washout required |
| Strong CYP2D6 inhibitors (bupropion, fluoxetine, paroxetine, quinidine) | Increased vortioxetine levels | Reduce vortioxetine dose by half |
| CYP inducers (rifampin, carbamazepine, phenytoin) | Decreased vortioxetine efficacy | Consider dose increase (max tolerated) |
| Serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, St. John's wort) | Serotonin syndrome risk | Use with caution; monitor closely |
| NSAIDs, aspirin, anticoagulants | Increased bleeding risk | Monitor for bleeding; consider gastroprotection |
CYP2D6 considerations: Vortioxetine is a substrate of CYP2D6. Poor metabolizers (7-10% of Caucasians, 2% of Asians) have doubled plasma concentrations. Dose reduction is recommended for known poor metabolizers. Conversely, ultrarapid metabolizers may require higher doses.
Other interactions:
- CNS depressants: Additive sedation with alcohol, benzodiazepines, or other CNS depressants.
- Diuretics: Increased risk of hyponatremia.
- Buspirone, lithium, tryptophan: May enhance serotonergic effects.
Vortioxetine does not significantly inhibit or induce CYP enzymes at therapeutic concentrations, minimizing its effect on other drugs metabolized by these pathways.
Clinical pearls
Distinguishing features: Vortioxetine's multimodal mechanism differentiates it from traditional SSRIs. The combination of SERT inhibition with 5-HT3 and 5-HT7 antagonism may provide cognitive benefits beyond mood improvement, making it a consideration for patients with cognitive symptoms accompanying depression.
Onset of action: Like other antidepressants, therapeutic effects typically require 4-6 weeks, though some patients may experience earlier improvement. Cognitive benefits may emerge as early as 2 weeks in some studies.
Sexual dysfunction: Clinical trial data suggest lower rates of sexual side effects compared to traditional SSRIs, though sexual dysfunction still occurs and should be monitored.
Switching strategies: When switching from another antidepressant, consider the half-life of the prior agent and risk of serotonin syndrome. No tapering of vortioxetine is required when switching to another antidepressant, but allow adequate washout before starting an MAOI.
Discontinuation: Taper gradually to minimize discontinuation symptoms. A reasonable approach is to reduce by 50% for one week, then discontinue. Longer tapers may be needed for patients on chronic therapy.
Exam tip: Vortioxetine is the answer when a question stem describes an antidepressant with cognitive benefits or mentions a "multimodal" mechanism involving both SERT inhibition and direct receptor modulation.
Comparative efficacy: Meta-analyses suggest efficacy comparable to other second-generation antidepressants for acute depression. Evidence for cognitive effects comes primarily from secondary analyses and dedicated cognitive batteries in depression trials.
Dosing: Typically initiated at lower doses and titrated as tolerated. Dosing follows product labeling and is individualized based on response and tolerability.
Practice questions
1. A 42-year-old woman with major depressive disorder reports persistent difficulty with concentration and memory at work despite improvement in her mood after 6 weeks of treatment with sertraline. She requests a medication that might better address her cognitive symptoms. Her psychiatrist decides to switch her to vortioxetine. Which of the following best describes vortioxetine's mechanism that may contribute to cognitive benefits?
2. A 35-year-old man has been taking vortioxetine 20 mg daily for depression. He is scheduled for surgery and his surgeon prescribes tramadol for postoperative pain management. Three days after starting tramadol, he presents to the emergency department with agitation, confusion, tremor, hyperreflexia, diaphoresis, and fever. What is the most likely diagnosis?
3. A 28-year-old woman with major depressive disorder has been taking vortioxetine 15 mg daily for 8 weeks with good response. Laboratory testing reveals a sodium level of 128 mEq/L (normal 135-145 mEq/L). She reports mild nausea but no other symptoms. Her only other medication is a thiazide diuretic for hypertension. Which of the following best explains her hyponatremia?
Frequently asked questions
How does vortioxetine work?
Vortioxetine works through a multimodal mechanism combining serotonin transporter (SERT) inhibition with direct modulation of multiple serotonin receptor subtypes. It acts as an antagonist at 5-HT3, 5-HT7, and 5-HT1D receptors, a partial agonist at 5-HT1B receptors, and an agonist at 5-HT1A receptors. This combination increases serotonin availability while fine-tuning receptor-mediated effects, potentially enhancing not only mood but also cognitive function through increased release of acetylcholine, dopamine, and norepinephrine in cortical regions.
What are the side effects of vortioxetine?
The most common side effect of vortioxetine is nausea, which is dose-dependent and the most frequent reason patients discontinue the medication. Other common side effects include constipation, vomiting, dizziness, dry mouth, diarrhea, and sexual dysfunction (though less frequent than with traditional SSRIs). Serious but rare effects include serotonin syndrome (especially with other serotonergic drugs), abnormal bleeding, hyponatremia (particularly in elderly patients), activation of mania in bipolar disorder, and discontinuation syndrome if stopped abruptly. Taking the medication with food may reduce gastrointestinal symptoms.
Is vortioxetine a controlled substance?
No, vortioxetine is not a controlled substance. It does not have abuse potential and is not scheduled under the Controlled Substances Act. Unlike benzodiazepines or stimulants, antidepressants including vortioxetine do not produce euphoria or dependence. However, abrupt discontinuation can lead to discontinuation syndrome with symptoms like dizziness, irritability, and sensory disturbances, so gradual tapering is recommended when stopping treatment.
Vortioxetine vs escitalopram — what is the difference?
The main difference is mechanism of action: escitalopram is a selective serotonin reuptake inhibitor (SSRI) that works solely by blocking the serotonin transporter, while vortioxetine has a multimodal mechanism combining SERT inhibition with direct modulation of multiple serotonin receptors (5-HT3, 5-HT7, 5-HT1D antagonism; 5-HT1B partial agonism; 5-HT1A agonism). This gives vortioxetine potential cognitive benefits beyond mood improvement. Both treat major depressive disorder, but vortioxetine may cause less sexual dysfunction and has a longer half-life. Escitalopram is generic and less expensive, while vortioxetine is a newer branded medication.
Can you take vortioxetine with other antidepressants?
Combining vortioxetine with other serotonergic antidepressants significantly increases the risk of serotonin syndrome and is generally not recommended. Vortioxetine is absolutely contraindicated with MAOIs, requiring a 14-day washout when switching between them. Concurrent use with SSRIs, SNRIs, or other serotonergic agents should be avoided due to additive serotonergic effects. If switching antidepressants, allow appropriate washout periods based on the half-life of the prior medication. In rare cases, clinicians may combine antidepressants under close monitoring, but this requires careful consideration of risks versus benefits.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N06AX26
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.